18F-FDG Uptake of Primary Tumors in Relation to Patient Clinical Parameters
| SUV category* | ||||
|---|---|---|---|---|
| Variable | Total patients | ≤5.5 (n = 11) | >5.5 (n = 10) | P |
| Comparison of numbers of patients | ||||
| Sex, M/F | 14/7 | 7/4 | 7/3 | 0.999† |
| Age, ≤60/>60 y | 18/3 | 9/2 | 9/1 | 0.999† |
| B symptoms, no/yes | 13/8 | 9/2 | 4/6 | 0.080† |
| ECOG PS, 0–1/≥2 | 19/2 | 10/1 | 9/1 | 0.999† |
| IPI score, 0–1/≥2 | 13/8 | 9/2 | 4/6 | 0.080† |
| LDH level, normal/elevated | 8/13 | 7/4 | 1/9 | 0.024† |
| Local invasion of primary tumor, no/yes | 14/7 | 10/1 | 4/6 | 0.024† |
| Lymph node involvement, no/yes | 14/7 | 8/3 | 6/4 | 0.659† |
| Ann Arbor stage, I–II/III–IV | 16/5 | 10/1 | 6/4 | 0.149† |
| Response to initial therapy, no/yes | 5/16 | 0/11 | 5/5 | 0.012† |
| Comparison of mean SUVs (±SD) | ||||
| B symptoms, no/yes | 4.8 ± 3.1 | 6.4 ± 2.1 | 0.070‡ | |
| IPI score, 0–1/≥2 | 4.6 ± 2.4 | 6.8 ± 3.0 | 0.070‡ | |
| LDH level, normal/elevated | 3.5 ± 1.4 | 6.7 ± 2.8 | 0.014‡ | |
| Local invasion of primary tumor, no/yes | 4.6 ± 2.1 | 7.3 ± 3.3 | 0.037‡ | |
| Response to initial therapy, no/yes | 4.5 ± 2.1 | 8.4 ± 2.9 | 0.010‡ | |